HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform

Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis

Sarah Palmer, Mary F. Kearney, Frank Maldarelli et al. · Journal of Clinical Microbiology · 2005 · 503 citations · Full text

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

John Gregson, Michele W. Tang, Nicaise Ndembi et al. · The Lancet Infectious Diseases · 2016 · 274 citations · Full text

Challenges and opportunities in estimating viral genetic diversity from next-generation sequencing data

Niko Beerenwinkel, Huldrych F. Günthard, Volker Röth et al. · Frontiers in Microbiology · 2012 · 248 citations · Full text

Engineering, Genetics, Genomics +22

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Jean‐Michel Molina, Anthony LaMarca, Jaime Andrade‐Villanueva et al. · The Lancet Infectious Diseases · 2011 · 171 citations

Daily Elvitegravir, Treatment And Prevention, Antiviral Drug Development +9

Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing

George Melikian, Soo‐Yon Rhee, Vici Varghese et al. · Journal of Antimicrobial Chemotherapy · 2013 · 133 citations · Full text